Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
114 results about "Gland cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A gland is a group of cells in an animal's body that synthesizes substances (such as hormones) for release into the bloodstream ( endocrine gland) or into cavities inside the body or its outer surface ( exocrine gland ).
Application of compounds in isorhodanic ester classes for treating diseases of prostate and skin cancer
ActiveCN101091705AIncreased ability to remove harmful substancesImprove in vitro dissolutionUrinary disorderEster active ingredientsDiseaseProstate cancer cell
The present invention relates to a method capable of using natural and artificial synthetic isosulfocyanate compound or its derivative to prevent and cure prostatic diseases and skin carcinoma. The internal tests show that various isosulfocyanate compounds or their derivatives can induce prostatic cell II phase drug metabolic detoxication enzyme-glutathione transferase so as to can inhibit the hyperplasia of prostate and inflammation, and can prevent and cure prostatic carcinoma and skin carcinoma.
Owner:JC (WUXI) CO INC
Compounds and methods for treating insulin resistance and cardiomyopathy
InactiveUS20060079542A1Avoid damageProtect enhance yieldBiocideOrganic chemistryCongestive heart failure chfInsulin resistance
Novel compounds, compositions comprising compounds, and methods for methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular system, atherosclerosis, sepsis, type 1 diabetes, liver damage, and cachexia, by administering compounds described herein. Compounds presented herein may be used to modulate serine palmitoyl transferase activity.
Owner:TRANSITION THERAPEUTICS INC
Method for screening cervical cancer
InactiveUS20050221399A1Effective diagnosisEfficient screeningBiological testingSquamous CarcinomasScreening method
The invention provides a reagent for diagnosing cervical cancer, which can not only detect the presence or absence of cervical cancer but can also distinguish squamous cell carcinoma and adenocarcinoma from each other, a method for screening cervical cancer by using the reagent, particularly a screening method capable high speed processing by utilizing flow cytometry. The reagent comprises a first labeled antibody reacting with gland cells, a second labeled antibody reacting with adenocarcinoma cells and a third labeled antibody reacting with atypical cervical squamous cells, the antibodies being labeled with mutually distinguishable labels respectively. Preferably, at least one selected from the group consisting of MUC1 antibody, cytokeratin 7 antibody, and cytokeratin 18 antibody is used as the first labeled antibody, at least one selected from the group consisting of cytokeratin 8 antibody and HIK1083 antibody is used as the second labeled antibody, and at least one member selected from the group consisting of NMP179 antibody, p16INK4A antibody, Ki-67 antibody, p53 antibody, p21 antibody, EMA antibody, CEA antibody and MIB-1 antibody is used as the third labeled antibody.
Owner:SYSMEX CORP
Method for screening cervical cancer
InactiveCN1677109AEfficient screeningChemiluminescene/bioluminescenceSurgerySquamous CarcinomasKeratin Antibody
The invention provides a reagent for diagnosing cervical cancer, which can not only detect the presence or absence of cervical cancer but can also distinguish squamous cell carcinoma and adenocarcinoma from each other, a method for screening cervical cancer by using the reagent, particularly a screening method capable high speed processing by utilizing flow cytometry. The reagent comprises a first labeled antibody reacting with gland cells, a second labeled antibody reacting with adenocarcinoma cells and a third labeled antibody reacting with atypical cervical squamous cells, the antibodies being labeled with mutually distinguishable labels respectively. Preferably, at least one selected from the group consisting of MUC1 antibody, cytokeratin 7 antibody, and cytokeratin 18 antibody is used as the first labeled antibody, at least one selected from the group consisting of cytokeratin 8 antibody and HIK1083 antibody is used as the second labeled antibody, and at least one member selected from the group consisting of NMP179 antibody, p16[INK4A] antibody, Ki-67 antibody, p53 antibody, p21 antibody, EMA antibody, CEA antibody and MIB-1 antibody is used as the third labeled antibody.
Owner:SYSMEX CORP
Classification system, methods and kit for classifying, predicting and treating breast cancer
InactiveUS20160146819A1Good understand and treat breast cancerSolid foundationBiocideOrganic active ingredientsCell phenotypeBreast cancer classification
A novel classification system for breast cancer based on normal breast cell phenotypes and various expression levels of estrogen receptor (ER), androgen receptor (AR), and vitamin D receptor (VDR). The various categories of the classification system are associated with different survival rates and prognoses. The invention includes a method of classifying breast cancer comprises measuring the levels of ER, AR, and VDR in the cancerous tissue, and classifying the breast cancer into one of the above-noted categories according to expression levels. The invention includes a method of predicting the prognosis of breast cancer in a patient and a method of determining a treatment regimen for breast cancer depending on the category in which the breast cancer is classified. The invention includes a method of treating breast cancer according to the expression profile of ER, AR, and VDR detected in the cancerous tissue. Kits for detecting the same are also provided.
Owner:UNIV OF MIAMI
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
InactiveUS6972319B1Good potencyStimulate insulin releasePeptide/protein ingredientsReceptors for hormonesDiseaseMammal
This invention provides novel peptides that function in vivo to stimulate insulin release from pancreatic beta cells in a glucose-dependent fashion. These insulin secretagogue peptides are shown to stimulate insulin release in rat islet cells in vitro, and in vivo. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VIP / PACAP-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.
Owner:BAYER CORPORATION +1
Modified human acidic fibroblast growth factor gene and recombinant vector and applications thereof
ActiveCN104513821ABiologically activeProliferative functionFermentationVector-based foreign material introductionNucleotideFactor ii
A modified human acidic fibroblast growth factor gene is disclosed. The nucleotide sequence of the gene is shown as the number 25 locus to the number 450 locus of SEQ ID NO.1. The sequence is designed according to codon preferences of bombyx mori, and can be normally expressed and translated in the bombyx mori. A recombinant vector containing the modified human acidic fibroblast growth factor gene is also disclosed. The recombinant vector comprises an enhanser hr3 and a secreting type sericin 1 promoter Ser1, specifically expresses a modified human acidic fibroblast growth factor in a middle silk gland cell of the bombyx mori, and secretes a recombinant protein to a sericin layer of silk. The obtained silk has bioactivity, has a function of promoting cell proliferation when the silk is directly used, and is a good medical material.
Owner:SOUTHWEST UNIVERSITY
New plasma membrane biomarkers preferentially expressed in pancreatic beta cells useful in imaging or targeting beta cells
ActiveUS20100322850A1Evaluate effectivenessEarly detectionDisease diagnosisDiagnostic recording/measuringDiseaseDendritic cell
The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration). The five specific features of the selected biomarkers are: 1) Preferentially expressed in pancreatic islets as compared to surrounding tissues; 2) Higher expression in pancreatic beta cells than in pancreatic alpha cells or than in other islet non-beta cells; 3) Expression levels in pancreatic beta cells are higher or comparable to glucokinase which is an enzyme specifically expressed in the pancreatic beta cell; 4) Located in the membrane and as such targetable with antibodies, peptides or small molecules which allows imaging, targeting and immunohistochemistry; and 5) Expression is not induced during the process of inflammation of the beta cell mass and the protein is not enriched in T-cells and dendritic cells or in other cells participating in the inflammation process.
Owner:UNIV LIBRE DE BRUXELIES +2
Method for establishing and identifying cynoglossus semilaevis testis cell line
InactiveCN102304491AFast growthHigh passaging frequencyMicrobiological testing/measurementMicroorganism based processesBottleCynoglossus semilaevis
The invention relates to a method for establishing and identifying a cynoglossus semilaevis testis cell line, which comprises the following steps: adopting a MEM (Minimum Essential Medium), adding 20 percent of fetal calf serum, 0.1 percent of B-mercaptoethanol, 2 ng / ml of human alkaline fibroblastic growth factors, 1 ng / ml of leukemia inhibiting factors, 1 nmol of sodium pyrurate and 1 nmol of glutamine and preparing into a complete medium; inoculating a tissue block into a culture bottle, overturning and inversely placing the bottle to culture for 3 h and positively placing the culture bottle after the tissue block is attached onto a wall, so that the tissue block is soaked into the culture medium for culture. A trypsin digestion method is adopted for subculturing cells. One cynoglossus semilaevis testis cell line is established by adopting the above method and is subcultured to fiftieth generations. Meanwhile, the invention also provides a method for identifying a chromosome of the established cell line and the level of a molecular marker and a method for identifying the sensitivity of the cell line to related viruses. The method for establishing the cynoglossus semilaevis testis cell line can be used for culturing other fish gland cells and establishing the cell line, thereby having wider promotion and application prospect.
Owner:YELLOW SEA FISHERIES RES INST CHINESE ACAD OF FISHERIES SCI
Method for preparing rainbow trout IHN(Infectious Haematopoietic Necrosis) inactivated vaccine
InactiveCN104189899ASafe preparationEfficient preparationMicroorganism based processesAntiviralsAntigenJuvenile fish
The invention discloses a method for preparing a rainbow trout IHN (Infectious Haematopoietic Necrosis) inactivated vaccine, which comprises the following steps: carrying out grinding, filtering and poison dipping processing on pancreas and livers of juvenile fish which is attacked, but is still alive, inoculating rainbow trout gonad (RTG) cells, carrying out blind passaging at 14 DEG C, keeping for 5 days when carrying out blind passaging on the tenth generation, and collecting cell poisonous fluid; inoculating chinook salmon embryonic (CHSE) cells, carrying out passaging at 14 DEG C, and raising the culture temperature by 1 DEG C when passaging for 5 generations each time until the culture temperature is raised to 20 DEG C; and adopting epithelioma papulosum cyprini (EPC) cells to continuously carry out passaging under the condition of 20 DEG C, passaging to the twelfth generation to obtain high-titer virus solution and carrying out inactivation to obtain the rainbow trout IHN inactivated vaccine. According to the preparation method, RTG-2, CHSE-214 and EPC cells are utilized to alternately culture rainbow trout IHN viruses at a specific environment temperature so as to obtain a high-titer IHNV (Infectious Hematopoietic Necrosis Virus) antigen and produce the inactivated vaccine; and the technical difficult problem that the high-titer IHNV antigen cannot be obtained through single cells is solved.
Owner:LANZHOU WEITESEN BIOTECH
Method for manufacturing pancreatic-hormone-producing cells
InactiveUS20130022986A1Efficient productionProduce efficientlyMetabolism disorderMicrobiological testing/measurementScreening methodPancreatic hormone
The present invention provides a method of more efficiently producing pancreas cells, particularly pancreatic hormone-producing cells, a method of stably producing pancreas cells in a large amount by more efficiently inducing differentiation of stem cells into pancreas cells, a medicament containing a pancreas cells and a screening method using the cells.A method of producing pancreatic hormone-producing cells, including subjecting stem cells to the following steps (1)-(4):(1) a step of cultivating stem cells in a medium containing an activator of activin receptor-like kinase-4,7 and a GSK3 inhibitor(2) a step of cultivating the cells obtained in the aforementioned step (1) in a medium containing an activator of activin receptor-like kinase-4,7(3) a step of cultivating the cells obtained in the aforementioned step (2) in a medium containing any one or more kinds selected from the group consisting of (a) retinoic acid receptor agonists, (b) at least one kind selected from the group consisting of inhibitors of AMP-activated protein kinase and / or activin receptor-like kinase-2,3,6, and BMP antagonists, and (c) inhibitors of activin receptor-like kinase-4,5,7(4) a step of cultivating the cells obtained in the aforementioned step (3).
Owner:TAKEDA PHARMA CO LTD
Pancreatic beta-cell mass biomarker
InactiveUS20110123443A1Reduced inflammatory activityMonitor efficacyBiocideIn-vivo radioactive preparationsPancreasBiomarker (petroleum)
A biomarker for pancreatic beta-cell mass comprising measuring the levels of CFC1 in the serum of a subject is described. The biomarker provides a noninvasive means for measuring pancreatic beta cell mass that is particularly useful for monitoring the efficacy of treatments for metabolic disorders such as Type I or Type II diabetes, including pancreatic islet cell transplantations.
Owner:MERCK SHARP & DOHME CORP
Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
ActiveUS20160039875A1Less susceptible to protease cleavageImprove bioavailabilityMetabolism disorderPeptide sourcesHamsterRecent onset
Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster Reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster Reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes. While not wishing to be bound by theory, optimized Reg3 gamma peptides increases beta cell generation by its demonstrated properties shown within of transforming ductal pancreatic cells into new islets.
Owner:PERLE BIOSCI
Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
InactiveUS7537891B2Improved prognosisContinue treatmentSugar derivativesPeptide/protein ingredientsDisease areaProtein-Tyrosine Kinases
The present invention describes polynucleotides that have been discovered to correlate to the relative sensitivity or resistance of cells, e.g., breast cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. Such polynucleotides comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., breast cancer, in which signaling through one or more of the aforementioned Src tyrosine and protein tyrosine kinases is involved with the disease process.
Owner:BRISTOL MYERS SQUIBB CO
Sex reversal siRNA of Chinese mitten crab and application of siRNA
InactiveCN109988763AAchieving sexual reversalIncrease success ratePeptidesOther foreign material introduction processesNucleotideInjury mouth
Owner:WEIFANG UNIV OF SCI & TECH
Methods for producing proteins using silkworm middle silk gland-specific gene expression system
Transgenic silkworms comprising GFP whose expression is regulated by the sericin gene promoter were produced. Observation of the silk glands of the last instar larvae of the silkworms showed fluorescence only in the middle silk glands. GFP was secreted from middle silkgland cells from around the spinning stage, indicating that GFP moved into the gland lumen. Finally, GFP was spun into cocoon filaments, and cocoons containing large amounts of GFP were produced. Thus, by using the promoter region of the sericin gene, recombinant proteins can be produced in the middle silk glands. Furthermore, the recombinant proteins produced in the middle silk glands were readily secreted into the lumen of the middle silk glands.
Owner:NAT INST OF AGROBIOLOGICAL SCI
In vitro pancreatic differentiation of pluripotent mammalian cells
This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (DE) medium comprising a TGFp ligand, fibroblast growth factor ( FGF), bone morphogenetic protein (BMP), a PI3K inhibitor and optionally a GSK3 β inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; FGF; retinoic acid; and a BMP inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising FGF, retinoic acid, a BMP inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising FGF. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells. These methods may be useful, for example, in producing pancreatic cells for therapy or disease modelling.
Owner:CAMBRIDGE ENTERPRISE LTD
Method for detecting prostate cancer exosome based on Fe3O4@ SiO2@ TiO2 nanoparticle enrichment and PSMA sensor
PendingCN112129939AFirmly connectedEasy to separateFluorescence/phosphorescenceProstate cancer cellOncology
The invention discloses a method for detecting prostate cancer exosome based on Fe3O4@ SiO2@ TiO2 nanoparticle enrichment and a PSMA sensor. The method comprises the following steps of: enriching exosome by adopting Fe3O4@ SiO2@ TiO2 nanoparticles, and then constructing a hairpin-shaped PSMA aptamer sensor to quantify the exosome by measuring the change of fluorescence intensity. By utilizing thedetection method, the exosome of prostate cancer cells can be successfully distinguished from the exosome of normal prostate cells, and the detection limit is 9 * 10 <3> exosomes / microliter. The method is used for clinical prostate cancer patient serum samples and normal human serum samples, can quickly and accurately detect prostate cancer patients, and is verified by a traditional ELISA method. The exosome enrichment method is simple and quick, the enrichment efficiency is high, exosome enrichment can be completed within 8 minutes, and the enrichment efficiency is 91.5%. The sensitivity ishigh, the specificity is high, the detection limit is 9 * 10 <3> exosomes / microliter, and clinical prostate cancer patients and healthy people can be remarkably distinguished.
Owner:NINGBO UNIV
Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
InactiveUS20060024684A1Highly beneficialMicrobiological testing/measurementTreatment responseGenomic DNA
Aspects of the present invention provide compositions and methods for prognosis of, and / or predicting the estrogen treatment outcome of breast cell proliferative disorder patients, and in particular of patients with breast carcinoma. In preferred embodiments, this is achieved, at least in part, by determining the expression level of PITX2, and / or the genetic or the epigenetic modifications of the genomic DNA associated with the gene PITX2. Additional aspects of the invention provide novel sequences, oligomers (e.g., oligonucleotides or peptide nucleic acid (PNA)-oligomers), and antibodies, which have substantial utility in the described inventive methods and compositions.
Owner:EPIGENOMICS AG
Compounds and methods of treating insulin resistance and cardiomyopathy
InactiveUS20090042772A1Avoid damageProtect enhance yieldBiocideOrganic chemistryDyslipidemiaThrombus
Owner:TRANSITION THERAPEUTICS INC
Therapeutics
The present invention relates to the use of a compound of formula (1): wherein: R1 comprises a carbonyl group and R2 is a hydrocarbyl group; optionally wherein said ring is further substituted; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in one or more of: modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; modulating calcium spikes in mammalian cells; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes by modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; treating diseases in one or more of brain, heart, and T-cells by modulating calcium spikes in mammalian cells.
Owner:POTTER BARRY VICTOR LLOYD +4
Composition with acne removing and repairing functions, application of composition in cosmetics, gel and preparation method of gel
ActiveCN113893209AGood restorativeInhibition of differentiationCosmetic preparationsAntipyreticBiotechnologyCentella asiatica extract
The invention discloses a composition with acne removing and repairing functions, application of the composition in cosmetics, gel and a preparation method of the gel, and relates to the field of cosmetics. The composition is prepared from salicylic acid, a centella asiatica extract, a white willow extract, 4-terpineol, a chlorella extract, ergothioneine, a pine mushroom extract, a barosma betulina leaf extract and 10-hydroxydecanoic acid. Salicylic acid compounded with the chlorella extract and ergothioneine components is adopted to efficiently balance skin microorganisms; various plant extracts are natural and safe and have mild functions; the 4-terpineol, the white willow bark extract and the like in the formula have remarkable antibacterial and anti-inflammatory effects; the barosma betulina leaf extract, the 10-hydroxydecanoic acid and other extracts can inhibit sebaceous gland cell differentiation to achieve an efficient oil-control effect; and the ergothioneine, the chlorella extract and other extracts have an efficient repairing effect on skin, so that the product has efficient repairing, anti-inflammation and oil control functions, and has a remarkable acne removing effect and high safety.
Owner:GUANGZHOU HAMMAY COSMETICS CO LTD
Lisofylline analogs and methods for use
InactiveUS20100105690A1Maintain its insulin secretory capabilityEffective treatmentBiocideOrganic chemistryLisofyllineStereochemistry
Analogs of a Lisofylline (LSF), and synthetic methods for the preparation of such analogs are provided. The analogs of LSF provided have the ability to protect cell viability, particularly the ability to protect pancreatic β-cells.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy
InactiveUS20070135450A1Avoid damageProtect enhance yieldBiocideOrganic chemistryDyslipidemiaThrombus
Novel compounds, compositions comprising compounds, and methods for methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular system, atherosclerosis, sepsis, type 1 diabetes, liver damage, and cachexia, by administering compounds described herein. Compounds presented herein may be used to modulate serine palmitoyl transferase activity.
Owner:FORBES MEDI TECH RES
Gene encoding labyrinthin, a marker for cancer
InactiveUS7329743B2Tumor rejection antigen precursorsMicroorganism based processesCancer preventionNucleotide
A cDNA molecule that encodes a protein designated Labyrinthin (Lab) is isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab), or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells.
Owner:OPUS CRYSTAL HLDG LTD
Methods of using EPHA2 for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
InactiveUS7504211B2Modulate effectImproved prognosisPeptide/protein ingredientsMicrobiological testing/measurementDisease areaProtein-Tyrosine Kinases
The present invention describes polynucleotides that have been discovered to correlate to the relative sensitivity or resistance of cells, e.g., breast cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. Such polynucleotides comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., breast cancer, in which signaling through one or more of the aforementioned Src tyrosine and protein tyrosine kinases is involved with the disease process.
Owner:BRISTOL MYERS SQUIBB CO
Marker and kit for auxiliary diagnosis of prostatic cancer
ActiveCN113462780AAchieve early diagnosisPromote proliferationOrganic active ingredientsMicrobiological testing/measurementOncologyCancer research
The invention belongs to the technical field of medical biology, and discloses a molecular marker-LncRNA SNHG11 for auxiliary diagnosis of prostatic cancer. The LncRNA SNHG11 is highly expressed in cancer tissues of prostatic cancer, and is lowly expressed in paracancerous normal tissues; moreover, the expression level of the LncRNA SNHG11 in a prostatic cancer cell line is obviously higher than that of a normal prostate cell line; proliferation, migration and invasion of prostatic cancer cells can be obviously inhibited by knocking down the expression level of the LncRNA SNHG11 gene. Therefore, the LncRNA SNHG11 can be used as a molecular marker for auxiliary diagnosis of the prostatic cancer; by detecting the expression level of the LncRNA SNHG11 in a sample, auxiliary diagnosis can be carried out on the prostatic cancer, and a reference basis is provided for clinical doctors to diagnose the prostatic cancer.
Owner:PEOPLES HOSPITAL OF HENAN PROV
Sow feed for improving the milk secretion amount and preparation method thereof
InactiveCN105053583AImprove palatabilityImprove digestibilityAnimal feeding stuffFish oilMortality rate
The present invention discloses sow feed for improving the milk secretion amount and a preparation method thereof. The feed consists of the following raw materials in parts by weight: soybean cake powder 150-180, dried small shrimps 30-40, potato powder 6-8, gynura cusimbua 3-5, cured fly maggot powder 15-20, pericarpium canavaliae 3-4, mushroom residues 4-6, bone meal 3-4, tomato juice 2-3, sansevieria trifasciata 1-2, fish oil 3-5, peanut seedlings 4-6, rice bran 4-5, silkworm chrysalis powder 8-10, grape skins 2-3, ecklonia kurome okam 4-6, galactogogues 6-8 and a proper amount of water. The feed can stimulate mammary gland development with the addition of the galactogogues to reduce the prolactin inhibiting factor (PIF) secretion, further increase the pituitary prolactin (PRL) secretion, activate gland cells, promote the milk secretion and increase the sow milk secretion amount. The feed is strong in palatability, high in digestibility and rich in nutrition, and can supplement nutritional needs of sows, improve immunity of the sows and piglets and reduce piglet mortality.
Owner:CHANGZHOU HEXIANG PLASTIC
Use of natural or artificial isorhodanate analog compound JC-5411 in preparing transcription factor SP1 inhibitor
InactiveCN1769268AGrowth inhibitionEffective preventionOrganic chemistryAerosol deliveryProstate cancer cellEccentric hypertrophy
The invention relates the isosulfocyanate compounds (ISOTHIOCYANATES), in other word, JC-5411 compounds, which can adjust the expression of androgen acceptor gene in cell by suppressing the expression of gene transcription factor SP1, and suppress the abnormal breeding function of prostate gland cell. With the little compound, it can suppress hamster benign hypertrophy of the prostate (BPH), which is induced by suppressed male sex hormone, and the growth of prostate gland cancer cell. The invention provides the new method of effectively preventing and treating the hypertrophy of the prostate and prostate gland cancer. The compound possesses the low side effect, steady chemical biology nature, low cost of manufacture, and broad adaptability.
Owner:JC (WUXI) CO INC
Recombination method and application of luciferase reporter gene with aquaporin 1 (AQP1) promoter to drug screening
InactiveCN103233031AMicrobiological testing/measurementVector-based foreign material introductionSjögren syndromeSalivary gland cell
The invention belongs to the technical field of bioengineering and in particular relates to a recombination method and application of a luciferase reporter gene with a human aquaporin 1 (AQP1) promoter to drug screening. The highly expressed AQP1 plays an important role in the salivary secretion process and is closely related to onset of Sjogren syndromes. In the invention, a 1868bp AQP1 promoter sequence is amplified from a personal genome by utilizing the gene engineering technology and is cloned onto a PGL2-luc vector to construct an AQP1 promoter-Luc expression vector. AQP1 expression is controlled by a promoter region. Constructing a salivary gland cell model with the AQP1 promoter is a key step for screening the traditional Chinese medicine ingredients which can treat the Sjogren syndromes. The drug screening cell model proves that ginseng and American ginseng ingredients at certain concentrations can promote transcription of the AQP1 promoter and the higher the concentrations are, the stronger the activity is, and can guide the drugs to be clinically applied to treat the Sjogren syndromes.
Owner:JILIN UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com